Cited by 340Renin-Angiotensin System StudiesHormonal Regulation and HypertensionCoagulation, Bradykinin, Polyphosphates, and Angioedema

The DOI matches its Crossref record.

RISE IN PLASMA CONCENTRATION OF ALDOSTERONE DURING LONG-TERM ANGIOTENSIN II SUPPRESSION

STAESSEN, J., LIJNEN, P., FAGARD, R., VERSCHUEREN, L. J., AMERY, A.·1981·Journal of Endocrinology

DOI 10.1677/joe.0.0910457

Open this paper in CoChat — free account

Abstract

The plasma concentration of aldosterone was followed in seven hypertensive patients before and during long-term angiotensin II suppression with the orally active angiotensin-I-converting-enzyme inhibitor, captopril. The plasma concentration of aldosterone decreased initially from 74 to 21 pg/ml (P less than 0.05) after 1 month of administration of captopril. Thereafter the plasma concentration of aldosterone began to rise and after 1 year reached a level of 165 pg/ml. During long-term captopril therapy the plasma renin activity remained increased and the plasma angiotensin II concentration suppressed. The mechanism responsible for the late rise of the plasma concentration of aldosterone during long-term angiotensin II suppression with captopril remains to be elucidated. A sizeable and lasting hypotensive effect was observed in all patients.

Integrity signals

Registry

Crossref · 10.1677/joe.0.0910457

Cites

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Still being checked.

Sorted by citations

Items 101–200 of 340

Effect of Aldosterone Antagonism on Exercise Tolerance, Doppler Diastolic Function, and Quality of Life in Older Women With Diastolic Heart Failure
Daniel, K. R., Wells, G., Stewart, K. P., Moore, B., & Kitzman, D. W. (2009) · Congestive Heart Failure · doi:10.1111/j.1751-7133.2009.00056.x · Cited by 37
Mineralocorticoid Receptor Antagonists in Heart Failure: An Update
Ferreira, J. P., Pitt, B., & Zannad, F. M. (2024) · Circulation Heart Failure · doi:10.1161/circheartfailure.124.011629 · Cited by 41
Plasma Aldosterone Is Increased in Class 2 and 3 Obese Essential Hypertensive Patients Despite Drug Treatment
Sarzani, R., Guerra, F., Mancinelli, L., Buglioni, A., Franchi, E., & Dessı̀-Fulgheri, P. (2012) · American Journal of Hypertension · doi:10.1038/ajh.2012.47 · Cited by 37
Limitations of angiotensin inhibition
Nobakht, N., Kamgar, M. K., Rastogi, A., & Schrier, R. W. (2011) · Nature Reviews Nephrology · doi:10.1038/nrneph.2011.29 · Cited by 37
Current Strategies to Achieve Further Cardiac and Renal Protection through Enhanced Renin-Angiotensin-Aldosterone System Inhibition
Alfie, J., Aparicio, L. S., & D., W. (2011) · Reviews on Recent Clinical Trials · doi:10.2174/157488711795177912 · Cited by 37
Structure–Activity Relationships, Pharmacokinetics, and in Vivo Activity of CYP11B2 and CYP11B1 Inhibitors
Papillon, J. P. N., Adams, C. M., Hu, Q., Lou, C., Singh, A. K., Zhang, C., Carvalho, J., Rajan, S., Amaral, A., Beil, M. E., et al. (2015) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b00407 · Cited by 37
Eplerenone
Moore, T. D., Nawarskas, J. J., & Anderson, J. R. (2003) · Heart Disease · doi:10.1097/01.hdx.0000089783.30450.cb · Cited by 36
Aldosterone Receptor Antagonists in the Medical Management of Chronic Heart Failure
Tang, W. H. W., Parameswaran, A. C., Maroo, A. P., & Francis, G. S. (2005) · Mayo Clinic Proceedings · doi:10.4065/80.12.1623 · Cited by 35
Comparison of the long-term effects of candesartan and olmesartan on plasma angiotensin II and left ventricular mass index in patients with hypertension
Tsutamoto, T., Nishiyama, K., Yamaji, M., Kawahara, C., Fujii, M., Yamamoto, T., & Horie, M. (2009) · Hypertension Research · doi:10.1038/hr.2009.192 · Cited by 35
Combination of half doses of angiotensin type 1 receptor antagonist and angiotensin-converting enzyme inhibitor in diabetic nephropathy
FUJISAWA, T., Ikegami, H., Ono, M., Nishino, M., Noso, S., KAWABATA, Y., & Ogihara, T. (2005) · American Journal of Hypertension · doi:10.1016/j.amjhyper.2004.08.001 · Cited by 35
Eplerenone: A Selective Aldosterone Receptor Antagonist for Patients with Heart Failure
Barnes, B. J., & Howard, P. A. (2004) · Annals of Pharmacotherapy · doi:10.1345/aph.1e306 · Cited by 34
Aldosterone Breakthrough Caused by Chronic Blockage of Angiotensin II Type 1 Receptors in Human Adrenocortical Cells: Possible Involvement of Bone Morphogenetic Protein-6 Actions
Otani, H., Otsuka, F., Inagaki, K., Suzuki, J., Miyoshi, T., Kano, Y., Goto, J., Ogura, T., & Makino, H. (2008) · Endocrinology · doi:10.1210/en.2007-1476 · Cited by 34
Eplerenone: A New Aldosterone Receptor Antagonist—Are the FDA's Restrictions Appropriate?
Sica, D. A. (2002) · Journal of Clinical Hypertension · doi:10.1111/j.1524-6175.2002.01510.x · Cited by 33
Plasma Aldosterone Concentrations Are Not Related to the Degree of Angiotensin-Converting Enzyme Inhibition in Essential Hypertensive Patients.
Sato, A., SUZUKI, Y., Shibata, H., & Saruta, T. (2000) · Hypertension Research · doi:10.1291/hypres.23.25 · Cited by 34
Long-Term Effects of Irbesartan and Atenolol on the Renin-Angiotensin-Aldosterone System in Human Primary Hypertension
Malmqvist, K. K., Öhman, K. P., Lind, L., Nyström, F. H., & Kahan, T. (2003) · Journal of Cardiovascular Pharmacology · doi:10.1097/00005344-200312000-00005 · Cited by 34
Direct Inhibition of Renin as a Cardiovascular Pharmacotherapy
Sepehrdad, R., Frishman, W. H., Stier, C. T., & Sica, D. A. (2007) · Cardiology in Review · doi:10.1097/crd.0b013e318093e43a · Cited by 34
Sudden Cardiac Death and the Role of Medical Therapy
Arshad, A., Mandava, A., Kamath, G. S., & Musat, D. L. (2008) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2007.12.003 · Cited by 32
Effects of canrenoate plus angiotensin-converting enzyme inhibitors versus angiotensin-converting enzyme inhibitors alone on systolic and diastolic function in patients with acute anterior myocardial infarction
Pasquale, P. D., Cannizzaro, S., Scalzo, S., Parrinello, G., Fasullo, S., Giambanco, F., Fatta, A., & Paterna, S. (2005) · American Heart Journal · doi:10.1016/j.ahj.2005.03.032 · Cited by 33
Aldosterone breakthrough from a pharmacological perspective
Mogi, M. (2022) · Hypertension Research · doi:10.1038/s41440-022-00913-4 · Cited by 32
Aldosterone Blockade in CKD: Emphasis on Pharmacology
Schwenk, M. H., Hirsch, J. S., & Bomback, A. S. (2015) · Advances in Chronic Kidney Disease · doi:10.1053/j.ackd.2014.08.003 · Cited by 32
Development and validation of a liquid chromatography–tandem mass spectrometric assay for Eplerenone and its hydrolyzed metabolite in human plasma
Zhang, J. Y., Fast, D. M., & Breau, A. P. (2003) · Journal of Chromatography B · doi:10.1016/s1570-0232(02)00964-9 · Cited by 32
Effects of eplerenone on transcriptional factors and mRNA expression related to cardiac remodelling after myocardial infarction
Enomoto, S., Yoshiyama, M., Omura, T., Matsumoto, R., Kusuyama, T., Kim, S., Izumi, Y., Akioka, K., Iwao, H., Takeuchi, K., et al. (2005) · Heart · doi:10.1136/hrt.2004.046540 · Cited by 32
Synthesis of annulated pyridines as inhibitors of aldosterone synthase (CYP11B2)
Martin, R. E., Lehmann, J., Alzieu, T., Lenz, M., Corrales, M. A. C., Aebi, J. D., Märki, H. P., Kuhn, B., Amrein, K. E., Mayweg, A. V. W., et al. (2016) · Organic & Biomolecular Chemistry · doi:10.1039/c6ob00848h · Cited by 32
Managing resistant hypertension: focus on mineralocorticoid-receptor antagonists
Yugar‐Toledo, J. C., Modolo, R., de Faria, A. P., & Moreno, H. (2017) · Vascular Health and Risk Management · doi:10.2147/vhrm.s138599 · Cited by 32
Eplerenone suppresses neointimal formation after coronary stent implantation in swine
Wakabayashi, K., Suzuki, H., Sato, T., Iso, Y., Katagiri, T., & Takeyama, Y. (2005) · International Journal of Cardiology · doi:10.1016/j.ijcard.2005.03.078 · Cited by 31
Effects of Spironolactone and Metoprolol on QT Dispersion in Heart Failere
Akbulut, M., Özbay, Y., İlkay, E., Karaca, I., & Arslan, N. (2003) · Japanese Heart Journal · doi:10.1536/jhj.44.681 · Cited by 31
Eplerenone improves vascular function and reduces platelet activation in diabetic rats.
Schäfer, A., Vogt, C., Fraccarollo, D., Widder, J., Flierl, U., Hildemann, S. K., Ertl, G., & Bauersachs, J. K. (2010) · PubMed · Cited by 30
Discovery of N-[5-(6-Chloro-3-cyano-1-methyl-1H-indol-2-yl)-pyridin-3-ylmethyl]-ethanesulfonamide, a Cortisol-Sparing CYP11B2 Inhibitor that Lowers Aldosterone in Human Subjects
Papillon, J. P. N., Lou, C., Singh, A. K., Adams, C. M., Ksander, G. M., Beil, M. E., Chen, W., Leung-Chu, J., Fu, F., Gan, L., et al. (2015) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b01545 · Cited by 30
G protein–coupled estrogen receptor: a promising therapeutic target for aldosterone-induced hypertension
Li, X., Kuang, W., Qiu, Z., & Zhou, Z. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1226458 · Cited by 30
Single- and repeated-dose pharmacokinetics of eplerenone, a selective aldosterone receptor blocker, in rats
Cook, C. S., Zhang, L., Ames, G. B., Fischer, J., Zhang, J., & Levin, S. (2003) · Xenobiotica · doi:10.1080/0049825021000049277 · Cited by 30
Aldosterone antagonists in the treatment of heart failure
Marcy, T. R., & Ripley, T. L. (2005) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp050041 · Cited by 30
Aldosterone breakthrough with benazepril in furosemide‐activated renin‐angiotensin‐aldosterone system in normal dogs
Lantis, A. C., Ames, M. K., Atkins, C. E., DeFrancesco, T. C., Keene, B. W., & Werre, S. R. (2014) · Journal of Veterinary Pharmacology and Therapeutics · doi:10.1111/jvp.12154 · Cited by 29
Neurohormonal modulation in chronic heart failure
FERRARA, R., Mastrorilli, F., Pasanisi, G., Censi, S., D'aiello, N., Fucili, A., Valgimigli, M., & Ferrari, R. (2002) · European Heart Journal · doi:10.1016/s0195-668x(02)80022-7 · Cited by 29
Influence of diabetes mellitus on changes in left ventricular performance and renal function produced by converting enzyme inhibition in patients with severe chronic heart failure
Packer, M., Lee, W. H., Medina, N., Yushak, M., Kessler, P., & Gottlieb, S. S. (1987) · The American Journal of Medicine · doi:10.1016/0002-9343(87)90213-0 · Cited by 29
ACE Inhibitors in Heart Failure: Prospects and Limitations
Pitt, B. (1997) · Cardiovascular Drugs and Therapy · doi:10.1023/a:1007795915009 · Cited by 28
Monotherapy of RAAS blockers and mobilization of aldosterone: A mechanistic perspective study in kidney disease
Gupta, G., Dahiya, R., Singh, Y. P., Mishra, A., Verma, A., Gothwal, S., Aljabali, A. A. A., Dureja, H., Prasher, P., Negi, P., et al. (2020) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2020.108975 · Cited by 27
Treatment of heart failure with ACE inhibitors and beta-blockers
van der Horst, I. C. C., Voors, A. A., & van Veldhuisen, D. J. (2007) · Clinical Research in Cardiology · doi:10.1007/s00392-007-0487-y · Cited by 27
Aldosterone in renal disease
Ibrahim, H. N., & Hostetter, T. H. (2003) · Current Opinion in Nephrology & Hypertension · doi:10.1097/00041552-200303000-00006 · Cited by 27
Aldosterone Synthesis and Cytokine Production in Human Peripheral Blood Mononuclear Cells
Miura, R., Nakamura, K., Miura, D., Miura, A., Hisamatsu, K., Kajiya, M., Hashimoto, K., Nagase, S., Morita, H., KUSANO, K. F., et al. (2006) · Journal of Pharmacological Sciences · doi:10.1254/jphs.fp0060801 · Cited by 27
Determinants of blood pressure reduction by eplerenone in uncontrolled hypertension
Jansen, P. M., Frenkel, W. J., van den Born, B. H., de Bruijne, E. L. E., Deinum, J., Kerstens, M. N., Arnoldus, J. H. A., Woittiez, A. J. J., Wijbenga, J. A. M., Zietse, R., et al. (2012) · Journal of Hypertension · doi:10.1097/hjh.0b013e32835b71d6 · Cited by 26
Plasma enalapril levels and hormonal effects after short‐ and long‐term administration in essential hypertension.
Johnston, C. I., Jackson, B. J., Larmour, I., Cubela, R. B., & CASLEY, D. J. (1984) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.1984.tb02602.x · Cited by 26
Current and novel pharmacologic approaches in advanced heart failure
O’Connor, C. M., Gattis, W. A., & Swedberg, K. B. (1998) · American Heart Journal · doi:10.1016/s0002-8703(98)70254-6 · Cited by 26
Aldosterone Synthase Inhibitors for Cardiorenal Protection: Ready for Prime Time?
Mazzieri, A., Timio, F., Patera, F., Trepiccione, F., Bonomini, M., & Reboldi, G. (2024) · Kidney & Blood Pressure Research · doi:10.1159/000542621 · Cited by 27
Stability-indicating RP-HPLC method for analysis of eplerenone in the bulk drug and in a pharmaceutical dosage form
Rane, V. P., Patil, K. R., Sangshetti, J. N., Yeole, R. D., & Shinde, D. B. (2009) · Acta Chromatographica · doi:10.1556/achrom.21.2009.4.8 · Cited by 25
Effect of Long-term Monotherapy with the Aldosterone Receptor Blocker Eplerenone on Cytoskeletal Proteins and Matrix Metalloproteinases in Dogs with Heart Failure
Rastogi, S., Mishra, S., Zacà, V., Alesh, I. G., Gupta, R. C., Goldstein, S., & Sabbah, H. N. (2007) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-007-6057-8 · Cited by 25
Aldosterone antagonists for preventing the progression of chronic kidney disease
Navaneethan, S. D., Nigwekar, S. U., Sehgal, A. R., & Strippoli, G. F. (2009) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007004.pub2 · Cited by 24
Novel pharmacological approaches to lowering blood pressure and managing hypertension
Sayer, M., Webb, D. J., & Dhaun, N. (2025) · Nature Reviews Cardiology · doi:10.1038/s41569-025-01131-4 · Cited by 26
Mineralocorticoid receptor antagonists, a class beyond spironolactone — Focus on the special pharmacologic properties of eplerenone
Seferovic, P. M., Pelliccia, F., Zivkovic, I., Ristić, A. D., Lalic, N. M., Seferović, J. P., Simeunović, D. S., Milinković, I., & Rosano, G. M. C. (2015) · International Journal of Cardiology · doi:10.1016/j.ijcard.2015.02.096 · Cited by 23
Reduction of Aldosterone Production Improves Renal Oxidative Stress and Fibrosis in Diabetic Rats
Matavelli, L. C., & Siragy, H. M. (2012) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0b013e318274d2ef · Cited by 23
Effects of mineralocorticoid receptor antagonist spironolactone on atrial conduction and remodeling in patients with heart failure
Kimura, M., Ogawa, H., Wakeyama, T., Takaki, A., Iwami, T., Hadano, Y., Mochizuki, M., Hiratsuka, A., Shimizu, A., & Matsuzaki, M. (2010) · Journal of Cardiology · doi:10.1016/j.jjcc.2010.11.006 · Cited by 23
Fiftieth anniversary of aldosterone: from discovery to cardiovascular therapy
Tan, L., Schlosshan, D., & Barker, D. (2004) · International Journal of Cardiology · doi:10.1016/j.ijcard.2004.05.004 · Cited by 23
Role of aldosterone in congestive heart failure
Weber, K. T., & Villarreal, D. (1993) · Postgraduate Medicine · doi:10.1080/00325481.1993.11701670 · Cited by 23
The effect of aldosterone-antagonist therapy on aortic elastic properties in patients with nonischemic dilated cardiomyopathy
Vizzardi, E., Pina, P. D., Caretta, G., Bonadei, I., Sciatti, E., Lombardi, C., D’Aloia, A., Curnis, A., & Metra, M. (2014) · Journal of Cardiovascular Medicine · doi:10.2459/jcm.0000000000000102 · Cited by 22
Non‐steroidal mineralocorticoid antagonists: Prospects for renoprotection in diabetic kidney disease
Dhaybi, O. A., & Bakris, G. L. (2020) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13983 · Cited by 23
A validated SPE–LC-MS/MS assay for Eplerenone and its hydrolyzed metabolite in human urine
Zhang, J. Y., Fast, D. M., & Breau, A. P. (2003) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/s0731-7085(02)00595-2 · Cited by 22
Agents in development for the treatment of diabetic nephropathy
Goh, S., Jasik, M., & Cooper, M. E. (2008) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.13.3.447 · Cited by 23
Use and side‐effect profile of spironolactone in a private cardiologist's practice
Williams, E. M., Katholi, R. E., & Karambelas, M. R. (2006) · Clinical Cardiology · doi:10.1002/clc.4960290405 · Cited by 22
Double-blind comparison between propranolol and bendroflumethiazide in captopril-treated resistant hypertensive patients
Staessen, J. A., Fagard, R., Lijnen, P. J., Verschueren, L. J., & Amery, A. K. P. C. (1983) · American Heart Journal · doi:10.1016/0002-8703(83)90199-0 · Cited by 22
Self-citation
Outcome studies in diabetic nephropathy
Mohanram, A., & Toto, R. D. (2003) · Seminars in Nephrology · doi:10.1016/s0270-9295(03)00061-5 · Cited by 22
Aldosterone as a Mediator of Progressive Renal Dysfunction: Evolving Perspectives.
Epstein, M. (2001) · Internal Medicine · doi:10.2169/internalmedicine.40.573 · Cited by 21
The effect of enalapril on furosemide‐activated renin–angiotensin–aldosterone system in healthy dogs
Lantis, A. C., Ames, M. K., Werre, S. R., & Atkins, C. E. (2015) · Journal of Veterinary Pharmacology and Therapeutics · doi:10.1111/jvp.12216 · Cited by 20
Improving Outcomes in Post–Acute Myocardial Infarction Heart Failure: Incorporation of Aldosterone Blockade into Combination Therapy to Optimize Neurohormonal Blockade
Pitt, B., Fonarow, G. C., Gheorghiade, M., DEEDWANIA, P. C., & Duprez, D. A. (2006) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2006.03.006 · Cited by 19
Aldosterone and the Heart: Still an Unresolved Issue?
Catena, C., Colussi, G., Nait, F., Martinis, F., Pezzutto, F., & Sechi, L. A. (2014) · Frontiers in Endocrinology · doi:10.3389/fendo.2014.00168 · Cited by 20
Effects of Spironolactone on Exercise Capacity and Neurohormonal Factors in Patients with Heart Failure Treated with Loop Diuretics and Angiotensin-Converting Enzyme Inhibitor
Kinugawa, T., Oginö, K., Kato, M., Furuse, Y., Shimoyama, M., Mori, M., Endo, A., Kato, T., Omodani, H., Osaki, S., et al. (1998) · General Pharmacology The Vascular System · doi:10.1016/s0306-3623(97)00396-0 · Cited by 20
Effects of dapagliflozin on renin-angiotensin-aldosterone system under renin-angiotensin system inhibitor administration
Isshiki, M., Sakuma, I., Hayashino, Y., Sumita, T., Hara, K., Takahashi, K., Shiojima, I., Satoh‐Asahara, N., Kitazato, H., Ito, D., et al. (2020) · Endocrine Journal · doi:10.1507/endocrj.ej20-0222 · Cited by 19
Renin inhibition in the treatment of diabetic kidney disease
Komers, R. (2013) · Clinical Science · doi:10.1042/cs20120468 · Cited by 19
The novel mineralocorticoid receptor antagonist finerenone in diabetic kidney disease: Progress and challenges
Yang, P., Huang, T., & Xu, G. (2016) · Metabolism · doi:10.1016/j.metabol.2016.06.001 · Cited by 19
Drug Insight: aldosterone-receptor antagonists in heart failure—the journey continues
Kalidindi, S. R., Tang, W. H. W., & Francis, G. S. (2007) · Nature Clinical Practice Cardiovascular Medicine · doi:10.1038/ncpcardio0914 · Cited by 19
Drospirenone for Oral Contraception and Hormone Replacement Therapy
Motivala, A. A., & Pitt, B. (2007) · Drugs · doi:10.2165/00003495-200767050-00001 · Cited by 19
Tratamiento médico de la insuficiencia cardíaca basado en la evidencia
Agustí, A., Durán, M., Cumplido, D. R., Diogène, E., Arnau, J. M., Rodríguez, J. C., Basilio, E. G., & Lorite, N. M. (2001) · Revista Española de Cardiología · doi:10.1016/s0300-8932(01)76387-7 · Cited by 19
Evidence for Aldosterone Antagonism in Heart Failure
Sethi, R., Vishwakarma, P., & Pradhan, A. K. (2024) · Cardiac failure review · doi:10.15420/cfr.2024.10 · Cited by 19
Treatment of Combined Aortic Regurgitation and Systemic Hypertension: Insights From an Animal Model Study
Couët, J., Gaudreau, M., Lachance, D., Plante, É., Roussel, É., Drolet, M., & Arsenault, M. (2006) · American Journal of Hypertension · doi:10.1016/j.amjhyper.2006.01.021 · Cited by 18
The Emerging Role of Aldosterone Synthase Inhibitors in Overcoming Renin–Angiotensin–Aldosterone System Therapy Limitations: A Narrative Review
Patel, S. K., Teoh, H., Saunthar, A., Yau, T. M., & Verma, S. (2025) · Cardiac failure review · doi:10.15420/cfr.2025.09 · Cited by 17
New approaches to the treatment of nephropathy in diabetes
Thomas, M. C., & Groop, P. (2011) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2011.591785 · Cited by 17
Chronic Kidney Disease and Albuminuria in Arterial Hypertension
Leoncini, G., Viazzi, F. C., & Pontremoli, R. (2010) · Current Hypertension Reports · doi:10.1007/s11906-010-0141-3 · Cited by 17
Eplerenone: A Review of Its Use in Patients with Chronic Systolic Heart Failure and Mild Symptoms
Dhillon, S. (2013) · Drugs · doi:10.1007/s40265-013-0098-z · Cited by 17
Pathophysiological Aspects of the Renin-Angiotensin-Aldosterone System in Acute Myocardial Infarction
Dargie, H. J., & Byrne, J. (1995) · European Journal of Cardiovascular Prevention & Rehabilitation · doi:10.1177/174182679500200502 · Cited by 17
Aldosterone and renal injury
Nishiyama, A., & Abe, Y. (2004) · Folia Pharmacologica Japonica · doi:10.1254/fpj.124.101 · Cited by 17
Chronic Heart Disease and Its Management
Bright, J. M., & Mears, E. A. (1997) · Veterinary Clinics of North America Small Animal Practice · doi:10.1016/s0195-5616(97)50128-8 · Cited by 17
Drug Therapy of Heart Failure: An Immunologic View
Desoky, E. S. E. (2010) · American Journal of Therapeutics · doi:10.1097/mjt.0b013e3181d169db · Cited by 17
Treatment of Heart Failure in Long-term Dialysis Patients: A Reappraisal
Wang, A. Y.-M., & Sanderson, J. E. (2011) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2011.01.014 · Cited by 16
The Effects of Spironolactone on Nephron Function in Patients with Diabetic Nephropathy
Üstündağ, A., Tuğrul, A., Üstündağ, S., Süt, N., & Demirkan, B. (2008) · Renal Failure · doi:10.1080/08860220802389342 · Cited by 16
Biological Actions and Metabolism of Currently Used Pharmacological Agents for the Treatment of Congestive Heart Failure
Saini-Chohan, H. K., & Hatch, G. M. (2009) · Current Drug Metabolism · doi:10.2174/138920009787846314 · Cited by 16
Evaluation of the aldosterone-blocking agent eplerenone in hypertension and heart failure
Casella, G., & Struthers, A. D. (2007) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.8.17.3053 · Cited by 16
Angiotensin-converting Enzyme Inhibitors in Heart Failure
Borek, M., Charlap, S., & Frishman, W. H. (1989) · Medical Clinics of North America · doi:10.1016/s0025-7125(16)30675-7 · Cited by 16
Absorption and Disposition of a Selective Aldosterone Receptor Antagonist, Eplerenone, in the Dog
Cook, C. S., Zhang, L., & Fischer, J. S. (2000) · Pharmaceutical Research · doi:10.1023/a:1007597713530 · Cited by 15
Efficacy, tolerance and hormonal effects of a new oral angiotensin converting enzyme inhibitor, ramipril (HOE 498), in mild to moderate primary hypertension
Karlberg, B. E., Lindström, T., Rosenqvist, U., & Öhman, K. P. (1987) · The American Journal of Cardiology · doi:10.1016/0002-9149(87)90063-4 · Cited by 15
Newer Drug Therapy for Congestive Heart Failure
Coodley, E. L. (1999) · Archives of Internal Medicine · doi:10.1001/archinte.159.11.1177 · Cited by 15
Serum potassium levels predict blood pressure response to aldosterone antagonists in resistant hypertension
Shlomai, G., Sella, T., Sharabi, Y., Leibowitz, A., & Grossman, E. (2014) · Hypertension Research · doi:10.1038/hr.2014.77 · Cited by 14
Heart Failure and Chronic Kidney Disease: Should We Use Spironolactone?
Agrawal, S., Agrawal, N., Garg, J., Gupta, T., Mohandas, R., & Segal, M. S. (2015) · The American Journal of the Medical Sciences · doi:10.1097/maj.0000000000000514 · Cited by 14
Comparative effect of canrenone or hydrochlorothiazide addition to valsartan/amlodipine combination on urinary albumin excretion in well-controlled type 2 diabetic hypertensive patients with microalbuminuria
Fogari, R., Derosa, G., Zoppi, A., Lazzari, P., D’Angelo, A., & Mugellini, A. (2014) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2014.874415 · Cited by 14
Role of bone morphogenetic proteins in adrenal physiology and disease
Johnsen, I. K., & Beuschlein, F. (2010) · Journal of Molecular Endocrinology · doi:10.1677/jme-10-0001 · Cited by 14
Significance of AT1 Receptor Independent Activation of Mineralocorticoid Receptor in Murine Diabetic Cardiomyopathy
Nagatomo, Y., Meguro, T., Ito, H., Koide, K., Anzai, T., Fukuda, K., Ogawa, S., & Yoshikawa, T. (2014) · PLoS ONE · doi:10.1371/journal.pone.0093145 · Cited by 14
Neurohormonal modulation in chronic heart failure
Ferrara, R., Mastrorilli, F., Pasanisi, G., Censi, S., D'aiello, N., Fucili, A., Valgimigli, M., & Ferrari, R. (2002) · European Heart Journal Supplements · doi:10.1093/ehjsupp/4.suppl_d.d3 · Cited by 14
Novel Drugs and Current Therapeutic Approaches in the Treatment of Heart Failure
Bonarjee, V., & Dickstein, K. (1996) · Drugs · doi:10.2165/00003495-199651030-00001 · Cited by 14
Eplerenone
Keating, G. M., & Plosker, G. L. (2004) · Drugs · doi:10.2165/00003495-200464230-00005 · Cited by 14
Microalbuminuria and plasma aldosterone levels in nondiabetic treatment-naïve patients with hypertension
Catena, C., Colussi, G., Martinis, F., Novello, M., & Sechi, L. A. (2017) · Journal of Hypertension · doi:10.1097/hjh.0000000000001476 · Cited by 13
The effects of angiotensin II receptor blockade with losartan on systemic blood pressure and renal and extrarenal prostaglandin synthesis in women with essential hypertension*
Smith, M. C. F., Barrows, S., Meibohm, A. R., Shahinfar, S., Simpson, R. L., Weigel, K., & Dunn, M. J. (1995) · American Journal of Hypertension · doi:10.1016/0895-7061(95)00361-4 · Cited by 13
Angiotensin-Converting Enzyme Inhibition and Parathyroid Hormone Secretion
Zaheer, S., Brown, J. M., Connors, M., Williams, J. S., Adler, G. K., & Vaidya, A. (2017) · International Journal of Endocrinology · doi:10.1155/2017/4138783 · Cited by 12
Role of Angiotensin Receptor-Neprilysin Inhibition in Heart Failure
Prenner, S. B., Shah, S. J., & Yancy, C. W. (2016) · Current Atherosclerosis Reports · doi:10.1007/s11883-016-0603-4 · Cited by 12

Authors: STAESSEN, J., LIJNEN, P., FAGARD, R., VERSCHUEREN, L. J., & AMERY, A.
ORCID: STAESSEN, J.
Venue: Journal of Endocrinology
Publisher: Bioscientifica
Published: 1981-12-01
Volume: 91
Issue: 3
Pages: 457-465
ISSN: 0022-0795 (ISSN-L)
1479-6805
DOI: 10.1677/joe.0.0910457
OpenAlex: W1971680322
Cited by: 339
References: 0
Citations by year: 2026: 5 · 2025: 4 · 2024: 6 · 2023: 5 · 2022: 8 · 2021: 5 · 2020: 8 · 2019: 5 · 2018: 6 · 2017: 6 · 2016: 8 · 2015: 10 · 2014: 20 · 2013: 7 · 2012: 14
FWCI: 1.77
Type: journal article
Language: en
Open access: closed
Locations: Journal of Endocrinology (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Renin-Angiotensin System Studies
Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hormonal Regulation and Hypertension
Health Sciences › Medicine › Hematology › Coagulation, Bradykinin, Polyphosphates, and Angioedema
Keywords: aldosterone, captopril, ACE inhibitors, hypertension, plasma renin activity, renin-angiotensin system, long-term drug therapy, hypotension
MeSH terms: Adult, Aldosterone, Angiotensin II, Captopril, Depression, Chemical, Female, Humans, Hypertension, Male, Middle Aged, Proline, Renin, Time Factors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

RISE IN PLASMA CONCENTRATION OF ALDOSTERONE DURING LONG-TERM ANGIOTENSIN II SUPPRESSION

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks